Recent News & Events

Marlinz Pharma launches innovative Tolcylen® Therapeutic and Daily Use Foot Soaks to help patients achieve optimal foot hygiene

February 1, 2022

Marlinz Pharma has launched an innovative foot soak line that utilizes the patented Tolcylen delivery vehicle in combination with exfoliators, moisturizers, cleansers, essential oils, sea salts, and Epsom salts. The Tolcylen Therapeutic Foot Soak is packaged in a carton of 5 single-use pouches and is ideal for short-term augmentation of treatments for typical skin and nail conditions and as a deep cleansing soak. The Tocylen Daily-Use Foot Soak is packaged in a large resealable bag and is formulated to be used routinely over an extended period of time to maintain optimal foot hygiene by cleansing, moisturizing, and protecting the skin and nails. 

Marlinz Pharma begins the process of extending Tolcylen® Antifungal/Nail Renewal Solution patent coverage into new countries in Europe, North & Central America, Asia and the Middle East

July 10, 2021

Marlinz Pharma’s Intellectual property team has gained the initial approval to file for foreign patent coverage of the Tolcylen® Antifungal/Nail Renewal Solution formulation.  The new round of applications for coverage includes Japan, Australia, Canada, Korea, Russia, India, Mexico and countries of the European Patent Union.  Over the past 3 years Marlinz Pharma has been awarded 5 different patents related to the innovative, first of their kind formulations of combined drugs, cosmetic and low surface tension delivery vehicle ingredients. The ability to emulsify unique combinations of ingredients into single, homogenous formulations has helped create better patient outcomes ranging from minor cosmetic conditions to chronic issues many have had to endure for decades.

Marlinz Pharma sponsored Onychomycosis multicenter, double-placebo controlled study ramps up enrollment with new study sites approvals

October 22, 2021

The Tolcylen® Onychomycosis study is following all FDA Phase II requirements and has added new sites to enhance enrollment to accelerate reaching the 144 total patient target at completion.  The 9-month trial is being led by the primary investigators, Scot Malay DPM and Peter Bregman DPM, and is scheduled to be completed in the fall of 2022.  The study was originally scheduled to be completed in 2021 but was delayed due to the Covid outbreak.

Tolcylen™ unit volume surpasses 750,000 units as of March 2021...

March 5, 2021

Marlinz Pharma has announced another significant milestone as Tolcylen™ products dispensed through our physician partners have reached a total of 750,000.  The Tolcylen™ product family continues to experience a repidly expanding customer base with over 99% account retention.  The entire Marlinz Pharma team would like to thank all of our dispensing partners for their continued support. 

Marlinz Pharma patient to physician referrals hit 3,200...

December 22, 2020 

Marlinz Pharma has continued to refer a growing number of patients seeking Tolcylen™ to a dispensing physician near them.  Internet search traffic for Tolcylen™ availability has hit an all time high and Marlinz Pharma is now referring up to 150 patients a month by phone, website, email and other communications.  To date over 3,200 total patient referrals have been made to Tolcylen™ diapensing clinics.

Marlinz Pharma opens climate controlled warehouse to enhance shipping and handle inventory needs...

October 16, 2020

Marlinz Pharma officials have executed a 5 year lease for a dedicated warehouse space with offices, climate controlled storage and loading docks to handle increased volume over the coming years.  The additional space will also house a chemical prep and formulation lab and small scale production capabilities for future vertical integration plans.  This is another major step in establishing the infrastructure to handle our future growth and quality control needs.

 

Marlinz Pharma closes 3rd Quarter of 2020 with another revenue record despite downward pressure from COVID...

October 1, 2020

Marlinz Pharma closed the 3rd Quarter of 2020 with a record month.  June 2020 revenues beat the previous single month record by over 35%.  With clinics being restricted or in some cases closed, and all trade shows, speaker events, sales rep calls and other meetings cancelled from March 15th on, Tolcylen™ revenues still outpaced all previous months.  The unexpected growth during the pandemic was possible only through strong brand loyalty and the ability of our dispensing partners to navigate pandemic restrictions while continuing to offer their patients safe, accessible care.

 

2023 Meetings / Conferences

AAPPM Fall Conference
NYSPMA Clinical Conference
NC Winter Scientific Conference
FPMA SAM Conference
ACFAS Annual Scientific Conference
Midwest Podiatry Conference
The Western Foot & Ankle Conference
APMA National